R&D Sponsored Why conditions like UTI call for new antibiotics Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.
R&D Alzheimer’s research: Cutting through the noise to find the ... A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.
R&D Six things we learned about the obesity market at LSX 2025 In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.
R&D The importance of understanding the differences between 503A... Inside the ecosystem of compounding pharmacies, 503A and 503B facilities are distinct.
R&D Driving innovation through partnership at AstraZeneca, with ... Nikhil Mutyal, head of search and evaluation for respiratory and immunology at AstraZeneca, discusses partnership and external innovation at LSX.
R&D What’s holding back precision medicine outside oncology? Precision medicine is finding success in cancer care, but not much elsewhere. The reasons why are often more economic than scientific.
News Major trial launched to explore GLP-1 benefit in dementia A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.